KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first antibody discovery and design, announced a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (“IFX-101”) program.
The first antibody in Infinimmune’s therapeutic drug development pipeline, IFX-101, targets atopic dermatitis and is designed to deliver superior efficacy with extended dosing intervals for improved patient quality of life. By sourcing antibodies directly from the human immune system, Infinimmune taps into a naturally optimized, safe, and effective therapeutic reservoir, rather than engineering from scratch. Infinimmune’s GLIMPSE™ platform – a protein language model trained solely on native human antibody sequences – learns from millions of successful immune responses to engineer superior antibodies that harness evolution-proven strategies with enhanced biologic properties. This combination creates a potent platform that’s uniquely differentiated in the biologics field.
“We are pleased to partner with KBI Biopharma to advance our lead antibody program,” said Wyatt McDonnell, Ph.D., CEO and Co-Founder, Infinimmune. “By combining our Anthrobody® and GLIMPSE™ platforms together with KBI’s development and manufacturing expertise, we’re positioned to rapidly advance toward clinical trials. Our human-first approach enables us to deliver what patients really need – more effective treatments with greater convenience. This collaboration is an important step in our mission to bring transformative, human-first antibodies to patients in need."
“KBI is proud to support Infinimmune in its effort to transform biologics and deliver safer, more effective antibody therapeutics,” said Katie Edgar, Chief Business Officer of KBI Biopharma. “Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune’s cutting-edge antibody discovery with KBI’s deep expertise in development and manufacturing capabilities.”
The IFX-101 program is progressing at KBI’s Cell Line Development Center of Excellence in Geneva, Switzerland, using KBI’s advanced monoclonal antibody development and manufacturing platform, SUREmAb™, powered by Selexis.
About Infinimmune
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908013845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LähiTapiola To Implement Guidewire Cloud Platform to Modernise Insurance Operations9.9.2025 11:08:00 CEST | Press release
LähiTapiola, the Finnish finance group and provider of insurance services, has extended its long-standing relationship with Guidewire (NYSE: GWRE) by choosing to migrate Guidewire InsuranceSuite from an on-premises environment to Guidewire Cloud Platform to power continuous insurance innovation, enhance value and increase business agility. LähiTapiola, which has around 1.8 million owner-customers and 3,800 employees, is a group of companies serving personal, farm, entrepreneur, corporate and institutional customers throughout Finland. Since 2017 LähiTapiola has been using Guidewire InsuranceSuite, a collection of core applications for policy administration, billing, and claims management. Used together, InsuranceSuite enables seamless end-to-end insurance processes for P&C insurers across all lines of business. LähiTapiola will be the latest insurer to migrate to Guidewire Cloud Platform, which combines resilient, trusted infrastructure with modular and interconnected cloud services to
OKQ8 Selects LTIMindtree to Accelerate its Next-Gen Digital Transformation Journey9.9.2025 10:30:00 CEST | Press release
Extends the multi-million-dollar strategic partnership through a renewed contract LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the renewal of its strategic partnership with OKQ8, one of the largest fuel companies in the Nordic region. This renewal underscores LTIMindtree’s role as a trusted technology partner, strengthening its collaboration with OKQ8 to support their digital transformation goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908583018/en/ Clas Artvin, Chief Information Officer, OKQ8 & Srinivas Rao, Executive Vice President and Chief Business Officer, LTIMindtree. The extended partnership will focus on optimizing OKQ8’s technology landscape, spanning Cloud and Infrastructure Management, Application Development and Maintenance for both modern and legacy systems, advanced Data Analytics, CRM, and ERP services powered by Microsoft Dynamics
'RevoAb™', A New Service for Antibody Developability Engineering9.9.2025 10:00:00 CEST | Press release
RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® is pleased to announce the launch of a new contract research service, 'RevoAb™'. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity. About RevoAb™ Since December 2023, RevolKa has offered contract research services for antibody engineering using aiProtein®, its AI-driven protein engineering technology, through FUJIFILM Wako Pure Chemical Corporation in Japan. RevoAb™ is a new online service for antibody developability engineering based on "RevolKa's Refined Naturalness Design concept," This refines antibody framework sequences to be close to those in naturally occurring antibodies. The pilot version was released in Japan in July 2025. Based on customer feedback, we are now launching an upgraded RevoAb™ world-wide. With RevoAb™, users can instantly access multiple antibody seq
Sisvel Appoints IP Leader to Head China Business and Establish Shenzhen Office9.9.2025 09:38:00 CEST | Press release
Sisvel has appointed Yixiong Zou to lead its operations in China. He will be responsible for steering the company’s licensing, programme management and business development efforts in the country, and will manage a new Sisvel office to be established in Shenzhen. Mr Zou joins the company as Managing Director, China and is the first person to hold this title. His appointment reflects the importance that Sisvel attaches to the Chinese market. In a career spanning more than 25 years, Mr Zou has held engineering, legal and licensing roles with major technology companies in both China and the United States. Most recently, he was Associate General Counsel at renewable energy technology company AESC US. Mr Zou attended Shanghai Jiao Tong University before relocating to the US, where he earned a bachelor’s degree in electrical engineering from Florida State University and a master’s degree in electrical engineering from the University of Southern California. After beginning his working life at
Autel Energy Collaborates with Phoenix Contact to Integrate High-Current CCS2 Technology into New Megawatt-Class Charging System9.9.2025 09:30:00 CEST | Press release
As part of its global product launch event “Infinite Power – Starting from Zero,” Autel Energy introduced a high-power charging system from the MaxiCharger DT1000 series, integrating Phoenix Contact’s latest 1,000A liquid-cooled CCS Type 2 cable and connector system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909054584/en/ Autel Energy showcased the MaxiCharger DT1000 terminal integrating Phoenix Contact’s latest liquid-cooled CCS2 cable and connector. This marks the first integration of Phoenix Contact’s 1,000A CCS2 technology into the MaxiCharger DT1000 series—expanding its capability to serve high-power applications such as heavy-duty vehicles, commercial fleets or even high-performance passenger cars, while enhancing thermal stability and system-level compatibility. “By integrating Phoenix Contact’s new CCS2 connector into our MaxiCharger DT1000, we can bring this technology into a complete system — from modular c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom